We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

12 hedge funds and large institutions have $1.15M invested in MiNK Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.14% less ownership

Funds ownership: 1.93% → 1.79% (-0.14%)

25% less funds holding

Funds holding: 16 → 12 (-4)

32% less capital invested

Capital invested by funds: $1.7M → $1.15M (-$552K)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
12
Holders Change
-4
Holders Change %
-25%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$22.3K
2
BlackRock
BlackRock
New York
+$779

Top Sellers

Rank Fund Capital Flow
1
SG
StoneX Group
New York
-$55.1K
2
JMPWA
JP Morgan Private Wealth Advisors
California
-$43.5K
3
Millennium Management
Millennium Management
New York
-$28K
4
FWA
Freedom Wealth Alliance
Wisconsin
-$8.66K
5
UBS Group
UBS Group
Switzerland
-$1.41K

INKT Hedge Fund Activity: Q1 2023 in Review

12 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q1 2023, worth a combined $1.15M — down 32% from $1.7M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of INKT and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $22.3K. The largest seller was StoneX Group, exiting entirely with an estimated $55.1K sold.

  • 12 institutional investors held MiNK Therapeutics (INKT) as of Q1 2023, down from 16 in Q4 2022.
  • Funds reported $1.15M of MiNK Therapeutics stock for Q1 2023, down 32% quarter-over-quarter.
  • 1 fund opened new MiNK Therapeutics positions in Q1 2023 and 5 closed out, a net change of -4 holders.
  • The largest MiNK Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $22.3K added.
  • The largest MiNK Therapeutics seller in Q1 2023 was StoneX Group, an estimated $55.1K sold.

Based on aggregated 13F filings for Q1 2023.